Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Scenario 1: Priority Review Granted (Q3 2027) BLA submitted: Q1 2027 FDA accepts filing: ~2 months later Priority review: ~6 months from acceptance PDUFA date / approval: Q3 2027 Launch: Q4 2027 Scenario 2: Standard Review (Most Likely Q1Q2 2028) BLA submitted: Q1 2027 FDA accepts filing: ~2 months later Standard review: 1012 months from acceptance PDUFA date / approval: Q1Q2 2028 Launch: Q2Q3 2028 Scenario 3: Complete Response Letter or Delays (Late 2028 or Beyond) Potential causes: an unexpected safety signal emerging during review, manufacturing or facility inspection issues, or the FDA requesting additional data via a Complete Response Letter
Omada's Chief Medical Officer Carolyn Bradner Jasik, MD provides an overview of GLP-1 medications and their history in the first part of a video blog series discussing Omada's clinical stance on GLP-1s.
However, adding even light movement can improve results and provide additional health benefits beyond weight loss
Optimizing Performance with MK-677 Discover the benefits, mechanisms, and uses of MK-677, a compound that stimulates growth hormone and IGF-1 production
Dudum told investors that the company's U.S
